Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

A. Bamford, A. Turkova, H. Lyall, C. Foster, N. Klein, D. Bastiaans, D. Burger, S. Bernadi, K. Butler, E. Chiappini, P. Clayden, M. Della Negra, V. Giacomet, C. Giaquinto, D. Gibb, L. Galli, M. Hainaut, M. Koros, L. Marques, E. NastouliT. Niehues, A. Noguera-Julian, P. Rojo, C. Rudin, H. J. Scherpbier, G. Tudor-Williams, S. B. Welch, (PENTA Steering Committee)

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long-term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first- and second-line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

Original languageEnglish
Pages (from-to)e1-e42
JournalHIV Medicine
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

HIV Infections
HIV-1
Acquired Immunodeficiency Syndrome
Guidelines
Pediatrics
Health
Therapeutics
Hepatitis C
Drug-Related Side Effects and Adverse Reactions
Hepatitis B
Coinfection
Health Status
Immune System
Tuberculosis
Morbidity
Drug Therapy
Mortality
Pharmaceutical Preparations

Keywords

  • antiretroviral therapy
  • child
  • HIV-1

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015 : optimizing health in preparation for adult life. / Bamford, A.; Turkova, A.; Lyall, H.; Foster, C.; Klein, N.; Bastiaans, D.; Burger, D.; Bernadi, S.; Butler, K.; Chiappini, E.; Clayden, P.; Della Negra, M.; Giacomet, V.; Giaquinto, C.; Gibb, D.; Galli, L.; Hainaut, M.; Koros, M.; Marques, L.; Nastouli, E.; Niehues, T.; Noguera-Julian, A.; Rojo, P.; Rudin, C.; Scherpbier, H. J.; Tudor-Williams, G.; Welch, S. B.; (PENTA Steering Committee).

In: HIV Medicine, Vol. 19, No. 1, 01.01.2018, p. e1-e42.

Research output: Contribution to journalArticle

Bamford, A, Turkova, A, Lyall, H, Foster, C, Klein, N, Bastiaans, D, Burger, D, Bernadi, S, Butler, K, Chiappini, E, Clayden, P, Della Negra, M, Giacomet, V, Giaquinto, C, Gibb, D, Galli, L, Hainaut, M, Koros, M, Marques, L, Nastouli, E, Niehues, T, Noguera-Julian, A, Rojo, P, Rudin, C, Scherpbier, HJ, Tudor-Williams, G, Welch, SB & (PENTA Steering Committee) 2018, 'Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life', HIV Medicine, vol. 19, no. 1, pp. e1-e42. https://doi.org/10.1111/hiv.12217
Bamford, A. ; Turkova, A. ; Lyall, H. ; Foster, C. ; Klein, N. ; Bastiaans, D. ; Burger, D. ; Bernadi, S. ; Butler, K. ; Chiappini, E. ; Clayden, P. ; Della Negra, M. ; Giacomet, V. ; Giaquinto, C. ; Gibb, D. ; Galli, L. ; Hainaut, M. ; Koros, M. ; Marques, L. ; Nastouli, E. ; Niehues, T. ; Noguera-Julian, A. ; Rojo, P. ; Rudin, C. ; Scherpbier, H. J. ; Tudor-Williams, G. ; Welch, S. B. ; (PENTA Steering Committee). / Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015 : optimizing health in preparation for adult life. In: HIV Medicine. 2018 ; Vol. 19, No. 1. pp. e1-e42.
@article{9a449f4ac428442ba5aa0f3bbddd3d5e,
title = "Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life",
abstract = "The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long-term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first- and second-line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.",
keywords = "antiretroviral therapy, child, HIV-1",
author = "A. Bamford and A. Turkova and H. Lyall and C. Foster and N. Klein and D. Bastiaans and D. Burger and S. Bernadi and K. Butler and E. Chiappini and P. Clayden and {Della Negra}, M. and V. Giacomet and C. Giaquinto and D. Gibb and L. Galli and M. Hainaut and M. Koros and L. Marques and E. Nastouli and T. Niehues and A. Noguera-Julian and P. Rojo and C. Rudin and Scherpbier, {H. J.} and G. Tudor-Williams and Welch, {S. B.} and {(PENTA Steering Committee)}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/hiv.12217",
language = "English",
volume = "19",
pages = "e1--e42",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015

T2 - optimizing health in preparation for adult life

AU - Bamford, A.

AU - Turkova, A.

AU - Lyall, H.

AU - Foster, C.

AU - Klein, N.

AU - Bastiaans, D.

AU - Burger, D.

AU - Bernadi, S.

AU - Butler, K.

AU - Chiappini, E.

AU - Clayden, P.

AU - Della Negra, M.

AU - Giacomet, V.

AU - Giaquinto, C.

AU - Gibb, D.

AU - Galli, L.

AU - Hainaut, M.

AU - Koros, M.

AU - Marques, L.

AU - Nastouli, E.

AU - Niehues, T.

AU - Noguera-Julian, A.

AU - Rojo, P.

AU - Rudin, C.

AU - Scherpbier, H. J.

AU - Tudor-Williams, G.

AU - Welch, S. B.

AU - (PENTA Steering Committee)

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long-term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first- and second-line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

AB - The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long-term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first- and second-line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

KW - antiretroviral therapy

KW - child

KW - HIV-1

UR - http://www.scopus.com/inward/record.url?scp=84922382127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922382127&partnerID=8YFLogxK

U2 - 10.1111/hiv.12217

DO - 10.1111/hiv.12217

M3 - Article

AN - SCOPUS:84922382127

VL - 19

SP - e1-e42

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 1

ER -